The results of breast cancer screening projects such as the HIP-trial in New York (Shapiro et al., 1982) , the DOMproject in Utrecht (Collette et al., 1984) , the Nijmegen screening project (Verbeek et al., 1984) , the Swedish trial (Tabar et al., 1985) and the screening programme in Florence (Palli et al., 1986) show a considerable reduction of breast cancer mortality. But even though it is no longer disputed that early detection and early treatment lower the mortality of breast cancer, some problems remain to be solved. One of the problems inherent to screening is that a number of women who have been identified by mammography as suspect for having malignant lesions will turn out to be false-positive cases at additional examinations (Peeters et al., 1987) .
A cohort study was (Kleinbaum et al., 1982) . As a reference group a sample was taken of all women who had never been referred. Because the 462 women with a falsepositive test result were referred in different screening rounds, the reference group was stratified accordingly on screening round and age. Analogously to women with a false positive screening test, all women who developed breast cancer within one year after their screening examination were not enrolled into the reference group. To increase statistical efficiency a 1:4 sample was taken, resulting in a reference group of 1,865 women with a true negative test result. Breast cancers occurring in both groups were histologically confirmed.
As was expected because of the design of the study, the distribution of age and follow-up time were similar in both groups. The mean age was 54.0 years for women with a false positive test result, and 53.8 years for true negatives. The mean follow-up time for women with a false positive test result was 62.8 months, compared with 64.0 months for the reference group. Sixteen breast cancer cases occurred among the group with a false-positive result in a total follow-up time of 28,811 months. The reference group had a total follow-up time of 117,604 months, during which 24 breast cancer cases were diagnosed. See Table I .
It can be concluded from Table I that the incidence rate for women with a false-postive test result was 0.56 per 1,000 months, which is significantly higher (P=0.0006) than the incidence rate of 0.20 per 1,000 months in the reference group. Next, the distribution of age and follow-up time of the breast cancer cases in both groups were compared. Women who developed breast cancer after a previous falsepositive test result were older when compared with women who developed breast cancer in the reference group (94% were 50 years or older, compared to 79% in the reference group). They also showed a shorter follow-up time. Sixtythree per cent turned out to have breast cancer within 2 years after the previous false-positive test result, while only 37% developed breast cancer in the reference group. These findings were not statistically significant. The histological pattern of the carcinomas is presented in Table II. Revision of all radiological, clinical, cytological and histological data of the cancer cases was performed in order to clarify the observed higher incidence in the false-positive group (see Table I ). In one case additional mammography did not confirm the original diagnosis and the patient had been discharged. In 6 of the 16 cases the mammographically detected lesion was not included in biopsy specimen. This can be explained by the lack of routine specimen X-ray of biopsies (Holland et al., 1985) in the early years of the screening programme or by poor radiologic localisation due to small diameter and/or deep situation of the tumour and/ or density of the breast. Some time lapsed before radiological tests and clinical examination were carried out. In three cases the suspect lesion was removed by biopsy, but not recognised as malignant on histological examination. Two of these lesions happened to be of a special type of Analysis of the remaining 4 cases showed that the mammographic lesion which initially necessitated referral was not the same as the cancer which developed later on. The occurrence of just 4 breast cancer cases in women with a false-positive screening test involving a total follow-up time of 28,503 months yields an incidence rate of 0.14 per 1,000 months, which does not differ significantly (P= 0.76) from the incidence rate for women of the reference group. The aim of this study was to find out whether a falsepositive screening result is a risk indicator for developing breast cancer. In our analysis the study population consisted of women with a history of a false-positive screening result: although they were referred because of suspect mammographical signs, no malignancy was diagnosed within one year after referral. Mammographical lesions known to be associated with benign breast disease, such as cysts or fibroadenoma, are no reason for referral in the screening programme for early detection of breast cancer as long as there are no complaints or mammographical signs suspect for cancer! Nor is a false-positive referral identical to histologically proven benign disease, Thirty per cent of the 462 women falsely referred never even had a biopsy. The purpose of this study was not to arrive at any conclusions about breast cancer risk in women with benign breast diseases (Peterson & Williams, 1980; Moskowitz et al., 1980; Webber & Boyd, 1986 ), but about the risk of breast cancer in women with a false-positive screening result. This risk was computed to be 2.7 times as high as that in a reference group of women who have been screened, but never referred because of an abnormality. After revision, the apparently increased risk disappeared. To avoid the pitfalls inherent to the diagnostic procedure of asymptomatic women referred from the screening programme, regular meetings should be held by the diagnostic team including the radiologist, the surgeon and the pathologist. It is also mandatory to follow carefully designed protocols in the diagnostic procedure. It should be borne in mind, however, that when a new screening programme is launched, a lack of experience in reading and judging screen detected lesions will inevitably manifest itself. Therefore radiologists, pathologists and surgeons should be trained for the specific requirements of diagnosis in a screening setting (Tabfar & Dean, 1987) . After revision the incidence rate in the false-positive group (0.14 per 1,000 months) turned out to be somewhat lower compared with the reference group (0.20 per 1,000 months). One possible explanation could be that some women of the reference group were classified as not having cancer at the screening examination, while they in fact already had cancer. Indeed, revision of the mammograms showed that in one patient breast cancer was present at the time of examination and in two others the location of the breast cancer which developed later on was not represented on the screening mammogram. The follow-up time was on average 5 years for both groups. This may be too short to find any increase in risk. So far, however, no evidence has been found for any increased risk for women who have had a-false-positive screening test, if they are very carefully examined. Even for women who had a follow-up time of more than 8 years (20% of our study population), no increased risk was observed either.
